More than 46 pharmaceutical companies announced their results for the first quarter. Who is happy and who is worried?

[Pharmaceutical Network Industry News] According to incomplete statistics, as of now, more than 46 pharmaceutical companies have disclosed their performance in the first quarter, and more than 80% are pre-happy
.

Among them, more than 10 companies such as Zhifei Bio, Tonghua Dongbao, Kangenbei, Brother Technology, Taienkang, and Dongbao Bio have doubled their net profits, and Jiu’an Medical has grown significantly.
The company’s net profit has increased from 30 million to over 10 billion yuan, a year-on-year increase of more than 400 times
.

Jiu'an Medical is a medical device company.
Its main products include electronic blood pressure monitors, blood glucose meters and other electronic medical equipment
.

It is reported that during the reporting period, the US subsidiary of Jiu'an Medical iHealth sold iHealth antigen detection kit products through its own channels and the Amazon platform, and signed major contracts and orders with customers
.

The increase in sales revenue of this product made an important contribution to the company's performance during the reporting period
.

It is worth noting that in December 2021, the Shenzhen Stock Exchange pointed out in the revision of the stock listing rules that in order to further reduce the disclosure burden of market entities, it is no longer mandatory to disclose quarterly earnings forecasts
.

However, in the near future, there are still a number of pharmaceutical companies that have announced their report cards for the first quarter of 2022, including Livzon Group, Yuandong Bio, Hengrui Medicine, Asymchem, BGI, Pien Tze Huang,
etc.

So, who is happy and who is worried? [Happy] Livzon Group: Net profit increased by 6.
47% year-on-year On April 21, Livzon Group disclosed the report for the first quarter of 2022
.

During the reporting period, the company achieved an operating income of 3.
479 billion yuan, a year-on-year increase of 3.
86%, and a net profit attributable to shareholders of the listed company of 553 million yuan, a year-on-year increase of 6.
47%
.

 　　Yuandong Bio: Net profit increased by 24.
28% year-on-year On April 22, Yuandong Bio released the first quarter results announcement that the company achieved operating income of about 269 million yuan in the first quarter, a year-on-year increase of 21.
56%; realized the net profit attributable to shareholders of the listed company About 53.
8 million yuan, a year-on-year increase of 24.
28%
.

 　　Jichuan Pharmaceutical: Net profit increased by 24.
28% year-on-year On April 22, Jichuan Pharmaceutical issued a first-quarter results announcement saying that in the first quarter of 2022, the company achieved operating income of about 269 million yuan, a year-on-year increase of 21.
56%; the realization of attributable to listed companies The net profit of shareholders was about 53.
8 million yuan, a year-on-year increase of 24.
28%
.

 　　Pien Tze Huang: Net profit increased by 21.
93% year-on-year On April 22, Pien Tze Huang disclosed the performance report for the first quarter of 2022.
The company achieved operating income of 2.
348 billion yuan, a year-on-year increase of 17.
3%; net profit attributable to shareholders of listed companies was 689 million yuan, a year-on-year increase of 21.
93.
%; basic earnings per share was 1.
14 yuan
.

 　　Asymchem: Net profit increased by 223.
59% year-on-year On April 20, Asymchem disclosed the report for the first quarter of 2022
.

During the reporting period, the company achieved operating income of 2.
062 billion yuan, a year-on-year increase of 165.
28%; net profit of 499 million yuan, a year-on-year increase of 223.
59%; basic earnings per share of 1.
91 yuan
.

 　　Wantai Bio: Net profit increased by 360.
18% year-on-year On April 15, Wantai Bio released the first quarter report of 2022, the company achieved operating income of 3.
171 billion yuan, a year-on-year increase of 284.
85%; net profit attributable to the parent was 1.
331 billion yuan, a year-on-year increase 360.
18%; basic earnings per share was 2.
19 yuan
.

 　　[Worry] BGI: Net profit decreased by 37.
06% year-on-year On April 22, BGI released its 2021 performance report and first-quarter transcript
.

Among them, the company will realize a net profit of 1.
462 billion yuan in 2021, a year-on-year decrease of 30.
08%, and plans to distribute 3.
5 yuan per 10; in the first quarter of 2022, it will realize a net profit of 330 million yuan, a year-on-year decrease of 37.
06%
.

 　　Hengrui Medicine: Net profit fell 17.
35% year-on-year On April 22, Hengrui Medicine announced that the company's net profit in the first quarter was 1.
237 billion yuan, a year-on-year decrease of 17.
35%
.

On the same day, Hengrui Medicine also disclosed its 2021 annual report.
In 2021, the company achieved a net profit of 4.
53 billion yuan, a year-on-year decrease of 28.
41%
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.